chr10-87864534-A-G
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PP2PP3_ModeratePP5
The NM_000314.8(PTEN):āc.65A>Gā(p.Asp22Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,798 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000314.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTEN | NM_000314.8 | c.65A>G | p.Asp22Gly | missense_variant | Exon 1 of 9 | ENST00000371953.8 | NP_000305.3 | |
PTEN | NM_001304717.5 | c.584A>G | p.Asp195Gly | missense_variant | Exon 2 of 10 | NP_001291646.4 | ||
PTEN | NM_001304718.2 | c.-641A>G | 5_prime_UTR_variant | Exon 1 of 9 | NP_001291647.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461798Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 727210
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Reported in a cohort of patients with suspected Cowden syndrome and/or Bannayane-Rileye-Ruvalcaba syndrome, although clinical details were not provided (PMID: 21659347); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24475377, 29706350, 29706633, 29785012, 21659347) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.D22G variant (also known as c.65A>G), located in coding exon 1 of the PTEN gene, results from an A to G substitution at nucleotide position 65. The aspartic acid at codon 22 is replaced by glycine, an amino acid with similar properties. This variant was reported in individuals with features consistent with PTEN hamartoma tumor syndrome (external laboratory communication; Ambry internal data). One study detected this alteration in 1/802 individuals referred for PTEN analysis; however, specific phenotypic information was not provided for the individual carrying this alteration (Pilarski R et al. J Med Genet, 2011 Aug;48:505-12). In another study, expression cloning in yeast and mammalian cells showed no PIP3-phosphatase activity and nuclear localization for this variant (Mingo J et al. Eur J Hum Genet, 2018 08;26:1180-1187). In a massively parallel functional assay using a humanized yeast model, lipid phosphatase activity for this variant was functionally deficient (Mighell TL et al. Am. J. Hum. Genet. 2018 05;102:943-955). In addition, this variant demonstrated wild type-like intracellular protein abundance in a massively parallel functional assay (Matreyek KA et al. Nat Genet, 2018 06;50:874-882). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This missense alteration is located in a region that has a low rate of benign missense variation (Lek M et al. Nature. 2016 Aug 18;536(7616):285-91; DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Firth H.V. et al. 2009. Am.J.Hum.Genet. 84, 524-533 (DOI: dx.doi.org/10/1016/j.ajhg.2009.03.010)). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at